Patients With Neuropathic Pain Have Poor Sleep Quality

Güntel, Murat; Hüzmeli, Esra Doğru; Melek, İsmet

doi:10.1097/nmd.0000000000001325

Cited by 9 publications

(5 citation statements)

References 21 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The total range of this scale is 0 to 21 [ 15 ]. We categorized sleep quality as good when the overall value (global score) was less than five, and as poor when it was five or more [ 16 ]. The S-LANSS scale might be employed as a credible research tool where values under 12 were categorized as non-neuropathic pain, whereas values of 12 or above were categorized as neuropathic pain.…”

Section: Methodsmentioning

confidence: 99%

A Cross-Sectional Study on Neuropathic Pain Associated With Quality of Sleep in Spondylosis Patients

Das,

Singh,

Agrawal

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Neuropathic pain (NP) is common in spondylosis patients. Cervical and lumbar spondylosis are more common in the elderly population. Spondylosis patients also suffer from poor quality of sleep (QOS). This study aims to find a correlation between NP and QOS in spondylosis patients. Methods: We conducted a cross-sectional study and analyzed data using the chi-square test to correlate the NP with QOS. The Pittsburgh Sleep Quality Index (PSQI) and the Leeds Assessment of Neuropathic Symptoms and Signs, Self-complete (S-LANSS) questionnaires were used to assess QOS and evaluate neuropathic pain, respectively. Spondylosis was diagnosed based on the history, clinical examination, and radiological findings. Results: A total of 72 spondylosis patients, with a mean age of 47.35 years, were included in this study. Out of 72 subjects, 52 (72.2%) patients had neuropathic pain (NP group), and 20 (27.8%) patients had non-neuropathic pain (non-NP group). In the NP group, 41 patients (78.8%) had poor QOS, while 11 (21.2%) had good QOS. In the non-NP group, eight (40%) had poor QOS, and 12 (60%) had good QOS. Conclusion: This study concludes that neuropathic pain is associated with poor quality of sleep in spondylosis patients.

show abstract

Section: Methodsmentioning

confidence: 99%

A Cross-Sectional Study on Neuropathic Pain Associated With Quality of Sleep in Spondylosis Patients

Das,

Singh,

Agrawal

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…The coexistence of insomnia and chronic musculoskeletal pain results in greater pain intensity and alterations in sleep homeostasis ( 42 ). Among patients with neuropathic pain, those with poor sleep quality experience more pain, more severe depressive states, and worse quality of life than patients with good sleep quality, with a positive correlation between sleep quality and emotional state ( 43 ). In patients with musculoskeletal disorders, poorer sleep quality is associated with higher pain levels, and a high frequency of poor sleep quality is more prevalent in females ( 44 ).…”

Section: Clinical Research On the Relationship Between Chronic Pain A...mentioning

confidence: 99%

Sleep disorders in chronic pain and its neurochemical mechanisms: a narrative review

Duo,

Yu,

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

Chronic pain (CP) is a prevalent problem, and more than half of patients with CP have sleep disorders. CP comorbidity with sleep disorders imposes immense suffering and seriously affects the patient’s quality of life, which is a challenging issue encountered by clinicians. Although the reciprocal interactions between pain and sleep have been studied to some degree, there is still a lack of awareness and comprehensive description of CP comorbidity with sleep disorders. In this narrative review article, we summarize the current knowledge about the present estimates of the prevalence of comorbid sleep disorders in CP patients, sleep detection methods, sleep characterization in CP, and the effect of sleep disorders on CP and current therapies. We also summarize current knowledge of the neurochemical mechanisms of CP comorbidity with sleep disorders. In conclusion, insufficient attention has been paid to the role of sleep disorders in CP patients, and CP patients should be screened for sleep disorders in the clinic. Special attention should be given to a possible risk of drug–drug interaction when using two types of drugs targeting pain and sleep simultaneously. The current insight into the neurobiological mechanisms underlying CP comorbidity with sleep disorders is still rather limited.

show abstract

“…Актуальность проблемы НБ в совокупности с депрессией и тревожными расстройствами в современном здравоохранении хорошо иллюстрируют результаты анализа базы публикаций Thomson Reuters Web of Science (WoS): в 2000 г. количество опубликованных статей по соответствующей тематике составляло 8, в 2020уже 106 (общее число публикаций за 20 лет -915) [8]. НБ и связанная с ней депрессия являются причинами нарушения качества сна: исследования продемонстрировали, что более 83% с НБ могут страдать той или иной формой бессонницы [9].…”

Section: Introductionunclassified

Use of gabapentin for neuropathic pain therapy: A view from perspective of evidence-based medicine

Butranova,

Zyryanov

2024

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

The aim of the study was to analyze the literature sources for pharmacodynamic and pharmacokinetic features of gabapentin, providing its use in patients with neuropathic pain, as well as a comparative evaluation of its efficacy and safety when used in different doses.Materials and methods. PubMed, Google Scholar, EMBASE, ResearchGate scientific information network and elibrary.ru databases were used as search resources. The keywords used for the search were “gabapentin”, “mechanism of action”, “gabapentin targets”, “gabapentin pharmacodynamics”, “pharmacokinetics”, “pharmacokinetic parameters”, “neuropathic pain”, and “randomized clinical trials”. The depth of the search was 26 years (from 1998 to 2024). This review resulted in 87 literature sources.Results. Neuropathic pain (NeP) is one of the most common types of chronic pain, characterized by a high prevalence among people of the working age. Effective pharmacotherapy aimed at eliminating the pain syndrome is a key tool for improving the quality of life and preserving the work capacity of patients. Heterogeneity of etiologic factors involved in the genesis of NeP indicates the need to use drugs the analgesic effect of which is based on weakening the transmission of pain impulses in the CNS. In clinical trials, gabapentin has demonstrated efficacy in reducing the severity of pain in patients with postherpetic NeP, painful diabetic neuropathy and many other conditions accompanied by NeP. The dose of gabapentin 300 mg/day is the initial dose in the therapy of NeP and requires a further slow titration depending on the patient’s response to therapy and tolerability of the drug, especially in elderly and senile patients, as well as in patients with an impaired renal function. According to the published data, the most pronounced analgesic effect is achieved in the patients against the background of the gabapentin administration at a dose of 3600 mg/day.Conclusion. Gabapentin is the drug of choice in the management of patients with NeP of different etiology and intensity. A satisfactory safety profile and pharmacodynamic effects make gabapentin possible, despite the long history of its use, to remain a relevant drug used by a wide range of physicians, specialties, for pharmacotherapy of NeP patients.

show abstract

Patients With Neuropathic Pain Have Poor Sleep Quality

Cited by 9 publications

References 21 publications

A Cross-Sectional Study on Neuropathic Pain Associated With Quality of Sleep in Spondylosis Patients

A Cross-Sectional Study on Neuropathic Pain Associated With Quality of Sleep in Spondylosis Patients

Sleep disorders in chronic pain and its neurochemical mechanisms: a narrative review

Use of gabapentin for neuropathic pain therapy: A view from perspective of evidence-based medicine

Contact Info

Product

Resources

About